Cobenfy™ (xanomeline and trospium hydrochloride) – New drug approval
September 26, 2024 - The FDA announced the approval of Bristol-Myers Squibb’s Cobenfy (xanomeline and trospium hydrochloride capsules) or the treatment of schizophrenia in adults.
Download PDF
